Home › Compare › IHHHF vs ABBV
IHHHF yields 1.76% · ABBV yields 3.06%● Live data
📍 IHHHF pulled ahead of the other in Year 4
Combined, IHHHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IHHHF + ABBV for your $10,000?
IHH Healthcare Berhad, an investment holding company, provides healthcare services in Malaysia, Singapore, Turkey, India, and internationally. It provides primary care services, such as treatment of basic health care services, outpatient treatment, routine check-ups, vaccinations, preventive care, and patient education services. The company also offers secondary services, including specialist consultation, local surgeries, emergency care, laboratory, diagnostics, and acute treatment services; tertiary care services comprising specialist consultative care, advanced treatment or complex surgery, and inpatient care services; and quaternary care services, such as organ transplants, neurosurgery, cardiac surgery, and reconstructive plastic surgery. In addition, it provides ancillary services, including diagnostics, analytical laboratory testing, therapeutic radiology, physiotherapy, and integrated rehabilitation and advanced molecular diagnostics services. Further, the company offers medical education; train and develop nurses, doctors, allied healthcare professionals; real estate investment trust services; operates dialysis centers; operates educational institutions, colleges, schools and other centers of learning, research, and education; and provides catering, laundry, and cleaning services for hospitals, as well as import and wholesales drug and medical materials. It operated approximately 15,000 licensed beds across 80 hospitals in 10 countries. IHH Healthcare Berhad was incorporated in 2010 and is based in Kuala Lumpur, Malaysia.
Full IHHHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.